Hero

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

1

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

2

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Discover all news

Carousel

Social Feed

@SimonBornschein Congrats to the team!

2 days ago

@SimonBornschein Congrats to the team!

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting.… https://t.co/344oo5cXq0

2 days ago

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting.… https://t.co/344oo5cXq0

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annua… https://t.co/ZclX4xGkZ8

1 week ago

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annua… https://t.co/ZclX4xGkZ8

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W

3 weeks ago

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W

@SimonBornschein Congrats to the team!

2 days ago

@SimonBornschein Congrats to the team!

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting.… https://t.co/344oo5cXq0

2 days ago

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting.… https://t.co/344oo5cXq0

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annua… https://t.co/ZclX4xGkZ8

1 week ago

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annua… https://t.co/ZclX4xGkZ8

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W

3 weeks ago

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W